Potential Utility of Circulating MicroRNA-483 as a Biomarker for IGF-II–Associated Non–Islet Cell Tumor Hypoglycemia
The Journal of Clinical Endocrinology & Metabolism · 2025
DOI: 10.1210/clinem/dgae879 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Mikiko Okazaki-Hada und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Metabolism and Nephrology, Graduate School of Medicine, Nippon Medical School, Tokyo 113-8603, Japan. Hauptthemen laut MEDLINE: Insulin-Like Growth Factor II, Hypoglycemia, MicroRNAs, Biomarkers, Tumor. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: JSPS KAKENHI, Foundation for Growth Science.
Abstract (Originalsprache)
Context
In most cases of non–islet cell tumor hypoglycemia (NICTH), high molecular weight forms of insulin-like growth factor II, commonly referred to as big IGF-II, cause hypoglycemia. MicroRNA-483 (miR-483), encoded within an intron of IGF2, has been suggested to be coexpressed with IGF-II.
Objective
The aim of this study is to demonstrate the utility and reliability of circulating miR-483 as a biomarker for diagnosis and therapeutic outcome of NICTH.
Methods
Sera from 145 cases of suspected NICTH, and postoperative sera from 25 surgical cases of confirmed NICTH were subjected to Western blot analysis and enzyme-linked immunosorbent assay for IGF-II and quantitative polymerase chain reaction analysis for miR-483-5p and -3p. Tissue miR-483 expression levels were compared between resected solitary fibrous tumors (SFTs) and their surrounding margins from 11 surgical cases.
Results
NICTH was confirmed in 100 out of 145 cases based on the detection of big IGF-II in their sera. Receiver operating characteristic curve analysis revealed that serum miR-483-5p had a better diagnostic ability for NICTH than serum IGF-II or the classical diagnostic marker the IGF-II to IGF-I ratio. Notably, serum miR-483-5p levels decreased significantly with the disappearance of big IGF-II after surgical tumor resection. Tissue miRNA-483-5p and -3p expression levels were significantly higher in resected SFT tissues than in their surgical margins.
Conclusion
Circulating miR-483-5p, derived from IGF-II-producing tumors, appears to be a more reliable biomarker for diagnosis and therapeutic outcome of NICTH than IGF-II or the IGF-II to IGF-I ratio. These findings highlight the clinical utility of miR-483-5p in the management of NICTH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Metabolism and Nephrology, Graduate School of Medicine, Nippon Medical School, Tokyo 113-8603, Japan.
- Islet Cell Exocytosis, Department of Clinical Sciences Malmö, Lund University, 214 28 Malmö, Sweden.
- Department of Biochemistry, Kagawa University Faculty of Medicine, Kagawa 761-0793, Japan.
- Tokyo Women's Medical University, Shinjuku-ku, Tokyo 162-8666, Japan.
ORCID-Profile: Mikiko Okazaki-Hada, Mototsugu Nagao, Lena Eliasson, Izumi Fukuda, Masato Iwabu
Förderung
- JSPS KAKENHI
- Foundation for Growth Science
Zitieren
APA
Okazaki-Hada, M., Nagao, M., Asai, A., Okada-Iwabu, M., Hizuka, N., Eliasson, L., Sugihara, H., Fukuda, I., & Iwabu, M. (2025). Potential Utility of Circulating MicroRNA-483 as a Biomarker for IGF-II–Associated Non–Islet Cell Tumor Hypoglycemia. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae879
Vancouver
Okazaki-Hada M, Nagao M, Asai A, Okada-Iwabu M, Hizuka N, Eliasson L, et al. Potential Utility of Circulating MicroRNA-483 as a Biomarker for IGF-II–Associated Non–Islet Cell Tumor Hypoglycemia. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgae879
BibTeX
@article{OkazakiHada2025,
author = {Okazaki-Hada, Mikiko and Nagao, Mototsugu and Asai, Akira and Okada-Iwabu, Miki and Hizuka, Naomi and Eliasson, Lena and Sugihara, Hitoshi and Fukuda, Izumi and Iwabu, Masato},
title = {Potential Utility of Circulating MicroRNA-483 as a Biomarker for IGF-II–Associated Non–Islet Cell Tumor Hypoglycemia},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
doi = {10.1210/clinem/dgae879}
}
EUVIMED